About Bristol-Myers Squibb, Princeton, New Jersey
Bristol-Myers Squibb, Princeton, New Jersey: A Global Biopharmaceutical Company
Bristol-Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey. The company is committed to discovering, developing and delivering innovative medicines to patients with serious diseases. Bristol-Myers Squibb has a rich history of more than 130 years of scientific innovation and commitment to improving the lives of patients.
The company's mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol-Myers Squibb focuses on areas such as oncology, cardiovascular disease, immunoscience and fibrosis. The company's portfolio includes some of the world's most widely used drugs for treating cancer and other serious illnesses.
Bristol-Myers Squibb has a strong presence in the United States as well as globally. The company operates in more than 60 countries worldwide with over 30 manufacturing sites across six continents. With its global reach and expertise in research and development (R&D), Bristol-Myers Squibb is well-positioned to address unmet medical needs around the world.
One of the key strengths of Bristol-Myers Squibb is its commitment to R&D. The company invests heavily in research programs aimed at discovering new treatments for serious diseases such as cancer, cardiovascular disease and immunological disorders. In addition to internal R&D efforts, Bristol-Myers Squibb also collaborates with academic institutions, government agencies and other companies on research projects.
Another strength of Bristol-Myers Squibb is its focus on patient-centricity. The company recognizes that patients are at the center of everything it does – from drug discovery through clinical trials to commercialization – and strives to ensure that patient needs are met throughout this process.
In recent years, Bristol Myers-Squibb has made significant progress in advancing its pipeline of innovative medicines for treating cancer and other serious illnesses. One example is Opdivo (nivolumab), an immune checkpoint inhibitor approved by regulatory authorities around the world for treating various types of cancer including melanoma, lung cancer and renal cell carcinoma.
In addition to Opdivo, Bristol Myers-Squibb has several other promising drugs under development including liso-cel (JCAR017) for treating relapsed or refractory large B-cell lymphoma; ide-cel (bb2121) for multiple myeloma; CC-486 (oral azacitidine) for acute myeloid leukemia; TYK2 inhibitor BMS986165 for psoriasis; deucravacitinid (BMS986218) vaccine candidate against COVID19 among others
Overall,Bristol Myers-Squibbs' commitment towards innovation coupled with their focus on patient-centricity makes them one among top biopharmaceutical companies globally.Their continued investment into R&D will enable them bring forth many more life-saving treatments which will benefit millions across globe suffering from various ailments .